| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
,
J A Anderson3,
P Jones4,
P Calverley5 on behalf of the TRISTAN study group
1 North West Lung Centre, Wythenshawe Hospital, Manchester, UK
2 Department of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium
3 Statistics and Programming, Biomedical Data Sciences, GlaxoSmithKline Research and Development, Greenford, UK
4 St George’s Hospital Medical School, London, UK
5 Department of Medicine, University Hospital Aintree, Liverpool, UK
Correspondence to:
Correspondence to:
Professor J Vestbo
North West Lung Centre, Wythenshawe Hospital, Manchester M23 9LT, UK; jorgen.vestbo{at}manchester.ac.uk
Background: Combined treatment with inhaled corticosteroids and long acting ß2 agonists is approved for the treatment of chronic obstructive pulmonary disease (COPD), but little is known about the onset of effect of the combination.
Methods: Data were used from 1465 patients with COPD entered into a large 1 year double blind trial with daily measurements of peak expiratory flow (PEF) and symptom scores.
Results: PEF was significantly higher after 1 day in patients treated with salmeterol 50 µg twice daily or the salmeterol/fluticasone propionate combination 50/500 µg twice daily than placebo. In patients treated with fluticasone propionate 500 µg twice daily alone, PEF differed from placebo after 2 days. The differences after 2 weeks compared with placebo were 16 l/min (95% confidence interval (CI) 11 to 21), 11 l/min (95% CI 6 to 16), and 27 l/min (95% CI 22 to 33) for salmeterol, fluticasone propionate, and the salmeterol/fluticasone propionate combination, respectively. For all treatments the effect on PEF after 2 weeks was comparable to that seen at the end of the study. The difference between the salmeterol/fluticasone propionate combination and placebo after 2 weeks as a percentage of baseline was similar for PEF and clinic forced expiratory volume in 1 second (FEV1). Differences in breathlessness scores were statistically significant after 1 day for the group treated with salmeterol alone and after 2 days for the combination group. The 2 week change in FEV1 was only partly indicative of a long term response in individual patients.
Conclusions: The effects of salmeterol and fluticasone propionate, alone or in combination, on PEF and breathlessness are seen within days and most of the obtainable effect on these parameters is reached within 2 weeks.
Keywords: chronic obstructive pulmonary disease; inhaled corticosteroids; long acting beta agonists; breathlessness; lung function
This article has been cited by other articles:
|
|
 |
|
  A. Agusti and J. B. Soriano Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship? Eur. Respir. Rev., December 1, 2006; 15(100): 68 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P M A Calverley Caring for the burden of COPD. Thorax, October 1, 2006; 61(10): 831 - 832. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fragaki, C. Kileztky, C. Trentesaux, J.-M. Zahm, O. Bajolet, M. Johnson, and E. Puchelle Downregulation by a long-acting beta2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L11 - L18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. O'Byrne, S. Pedersen, W. W. Busse, W. C. Tan, Y.-Z. Chen, S. V. Ohlsson, A. Ullman, C. J. Lamm, and R. A. Pauwels Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma Chest, June 1, 2006; 129(6): 1478 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Donohue Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
